Dizone Tablet (Disulfiram 250mg)

Description

Dizone Tablet (Disulfiram 250mg) — Complete Clinical and Patient Information Guide

Product Overview

Dizone Tablet (Disulfiram 250mg) contains Disulfiram 250mg as its active pharmaceutical ingredient, belonging to the aldehyde dehydrogenase inhibitor — aversion therapy agent for alcohol dependence. It is clinically indicated for alcohol dependence — as an adjunct to counselling and psychosocial support in motivated patients who are committed to alcohol abstinence. This comprehensive guide has been developed in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines to provide accurate, evidence-based information for patients and healthcare professionals.

Dizone 250mg provides disulfiram at the 250mg dose for alcohol dependence aversion therapy. Dizone 250mg provides the standard maintenance dose of disulfiram for alcohol dependence aversion therapy, offering a well-established deterrent to alcohol consumption when taken daily by motivated patients committed to sobriety. Disulfiram’s greatest clinical value is in highly motivated patients who use it as a daily commitment device — the knowledge that drinking will cause an unpleasant and potentially dangerous reaction provides a powerful pharmacological deterrent supporting the patient’s own commitment to abstinence.

Understanding Dizone 250mg and Its Active Ingredient

Disulfiram 250mg is the pharmacologically active compound in Dizone 250mg. The drug class to which it belongs — aldehyde dehydrogenase inhibitor — aversion therapy agent for alcohol dependence — has a well-established clinical evidence base developed across decades of research, regulatory review, and real-world clinical use. Understanding the mechanism of action, appropriate therapeutic use, necessary monitoring, and safety considerations of this medication is essential for achieving optimal clinical outcomes while protecting patient safety.

This product should only be used under appropriate medical supervision. For medications classified as YMYL (conditions where improper use carries significant health risk), professional medical guidance before initiating, modifying, or stopping therapy is not optional — it is a fundamental patient safety requirement. Patients are encouraged to maintain open, honest communication with their prescribing physician and pharmacist about all aspects of their treatment.

Mechanism of Action

Disulfiram (tetraethylthiuram disulfide) is an aversion therapy agent for alcohol dependence, operating through an irreversible enzyme inhibition mechanism. Disulfiram irreversibly inhibits aldehyde dehydrogenase (ALDH2 and ALDH1A1) — the hepatic enzyme responsible for oxidising acetaldehyde (the toxic metabolite of ethanol produced by alcohol dehydrogenase) to the harmless acetate. When a patient taking disulfiram consumes any amount of alcohol, ethanol is metabolised normally to acetaldehyde by alcohol dehydrogenase, but acetaldehyde cannot be cleared by ALDH (which disulfiram has permanently inactivated). Toxic acetaldehyde rapidly accumulates, producing the severe and intensely aversive disulfiram-ethanol reaction (DER): within 5–15 minutes of alcohol consumption, patients experience flushing of the face and neck, tachycardia, palpitations, severe headache, nausea and vomiting, profuse sweating, hypotension, dyspnoea, hyperventilation, and profound malaise. The intensity of the DER is proportional to the dose of both disulfiram and alcohol. Severe reactions can include hypotension requiring vasopressors, cardiac arrhythmias, myocardial infarction, respiratory depression, and death — particularly in patients with cardiovascular disease or who consume large amounts of alcohol. The pharmacological aversion created by this reaction — the knowledge that any alcohol consumption will produce profound illness — supports sobriety through conditioned aversion reinforcement.

Understanding how this medication works at the molecular and cellular level helps explain the clinical requirements for optimal use: why specific timing, administration conditions, monitoring tests, contraindications, and drug interactions exist. Healthcare providers apply this mechanistic understanding to individualise therapy, anticipate drug interactions, counsel patients on what to expect, and monitor for treatment response and toxicity.

Clinical Indications

Dizone Tablet (Disulfiram 250mg) is clinically indicated for:

• Primary indication: alcohol dependence — as an adjunct to counselling and psychosocial support in motivated patients who are committed to alcohol abstinence
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of this specific medication for the individual patient. Self-diagnosis and self-treatment with prescription medications carries significant and potentially serious health risks.
• Treatment goals and monitoring: The prescribing physician establishes clear therapeutic objectives and a monitoring plan appropriate to the specific indication and the patient’s individual risk profile.

Dosage and Administration

Take Dizone 250mg 250mg once daily, usually in the morning. It can be taken with or without food. Never give disulfiram without the patient’s full knowledge and informed consent — covert administration is ethically and legally unacceptable. Wait at least 12 hours after the patient’s last alcoholic drink before starting disulfiram (ideally 24–48 hours). Never administer if the patient is under the influence of alcohol. Tablet must be administered under supervision initially — some programmes use observed daily dosing.

Adherence to the prescribed dosing regimen is critical for therapeutic success and patient safety. Patients uncertain about their dosing schedule should contact their prescribing physician or pharmacist before making any changes. Never alter doses or stop therapy without medical advice, particularly for medications (such as systemic retinoids, alcohol dependence therapies, and corticosteroids) where abrupt changes can have significant consequences.

Who Should Use Dizone 250mg

Dizone 250mg is indicated for adult patients (and where specified, adolescent patients) who have been diagnosed by a qualified healthcare professional with the conditions listed in the indications section, and for whom this medication has been determined appropriate following assessment of individual benefits and risks. Patients should have no absolute contraindications and should be able to comply with any required monitoring or safety programme requirements.

Contraindications — Who Should Not Use Dizone 250mg

Patient’s lack of knowledge or informed consent (disulfiram must never be given covertly). Cardiovascular disease (disulfiram-ethanol reaction can precipitate arrhythmia or MI in cardiac-compromised patients). Significant hepatic disease (disulfiram is hepatotoxic — contraindicated in active hepatitis or cirrhosis; monitor LFTs). Psychosis or severe mental illness. Peripheral neuropathy. Pregnancy. Hypersensitivity to disulfiram. Renal impairment (dose adjustment required). Current alcohol use (any amount within 12–24 hours of dosing).

Before starting Dizone 250mg, patients must provide their prescribing physician with a complete medical history, including all current medications (prescription and over-the-counter), known allergies, and relevant personal and family medical history. Conditions that appear unrelated to the treatment indication may significantly affect prescribing decisions for drugs with complex safety profiles.

Drug Interactions

Alcohol (any source — including mouthwash, cooking wine, alcohol-containing medicines, vinegar-based sauces): disulfiram-ethanol reaction — potentially life-threatening. Metronidazole: psychosis and confusion risk (similar mechanism). Warfarin: disulfiram inhibits CYP2C9, increasing warfarin plasma levels — significant bleeding risk; monitor INR closely and reduce warfarin dose. Phenytoin: disulfiram inhibits phenytoin metabolism — increased phenytoin levels and toxicity risk; monitor phenytoin levels. Benzodiazepines: disulfiram slows diazepam metabolism — increased sedation and toxicity risk. Isoniazid: neurological effects (CNS toxicity). Caffeine: disulfiram slows caffeine metabolism.

Drug interactions can be clinically significant and potentially dangerous. A complete medication review by a qualified pharmacist or physician is essential before starting Dizone 250mg. Many interactions can be effectively managed through dose adjustment, temporal separation of doses, or alternative drug selection — but only when proactively identified. Patients should never add new medications (including herbal supplements and over-the-counter products) without checking for interactions with Dizone 250mg.

Adverse Effects and Side Effects

Drowsiness and fatigue (common, particularly during first 2 weeks). Metallic or garlic-like aftertaste. Skin reactions (acneiform rash). Hepatotoxicity (rare but serious — monitor LFTs before starting and every 2 weeks for the first 3 months, then every 6 months; discontinue if significant transaminase elevation). Peripheral neuropathy with prolonged high-dose use. Psychosis (rare). Disulfiram-ethanol reaction (if patient consumes alcohol): flushing, tachycardia, palpitations, nausea, vomiting, hypotension, headache, dyspnoea — potentially severe or fatal in high-risk patients.

Side effects vary in frequency, severity, and clinical significance. Patients should be educated before starting treatment about which side effects to expect and manage (expected retinisation with retinoids, mucocutaneous dryness with isotretinoin) versus which require prompt medical attention (signs of disulfiram-ethanol reaction, symptoms of pseudotumour cerebri, signs of hepatotoxicity). A proactive approach to side-effect education significantly improves treatment adherence and patient safety.

Special Population Considerations

Alcohol dependence — integrated treatment: Pharmacotherapy alone is rarely sufficient for sustained recovery from alcohol dependence. All pharmacological treatments are most effective when integrated with psychosocial interventions — cognitive behavioural therapy (CBT), motivational enhancement therapy (MET), 12-step facilitation, SMART Recovery, or other structured support programmes. The combination of medication and psychological support produces significantly better outcomes than either alone.

Medical supervision: Management of alcohol dependence and withdrawal is a medically complex area requiring specialist input. Alcohol withdrawal can be life-threatening (delirium tremens, Wernicke’s encephalopathy, seizures) and requires supervised management. Never attempt alcohol withdrawal without medical assessment and supervision, particularly after heavy or prolonged alcohol use.

Liver monitoring: Most pharmacotherapies for alcohol dependence require baseline and periodic liver function tests, as many patients with alcohol use disorder have underlying hepatic damage that may influence drug metabolism and toxicity. Disulfiram and naltrexone particularly require regular liver function monitoring.

Concurrent mental health: Depression, anxiety, PTSD, and other mental health conditions co-occur with alcohol dependence in the majority of patients. Comprehensive management should screen for and address comorbid psychiatric conditions, which if untreated significantly increase relapse risk.

Informed consent is non-negotiable: Disulfiram must only be prescribed with the patient’s full knowledge and explicit informed consent. The patient must understand the disulfiram-ethanol reaction in detail — including that the reaction can be severe and potentially fatal. Covert administration is ethically unacceptable and illegal in most jurisdictions.

Duration: Disulfiram is typically continued for 12–24 months as part of a comprehensive alcohol dependence treatment programme. Do not stop abruptly without medical guidance — the protective aversion effect is lost within 1–2 weeks of stopping, increasing relapse risk.

Storage and Handling

Store Dizone 250mg at room temperature (15–25°C) in a dry location away from direct sunlight, heat sources, and moisture. Keep in the original manufacturer’s packaging until required. Secure out of reach of children and pets. Do not use beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back services — do not flush down drains or discard in household waste, as pharmaceutical waste poses environmental hazards.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children and pets. Do not use beyond the printed expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember, unless it is nearly time for the next scheduled dose. Never double-dose. Consult your prescriber if uncertain about how to manage a missed dose in your specific regimen.

Q: What happens if I drink alcohol while taking disulfiram?
A: Within 5–15 minutes of consuming any alcohol (even small amounts like mouthwash or cooking wine), you will experience the disulfiram-ethanol reaction: intense facial flushing, severe headache, rapid heartbeat, nausea, and vomiting. In severe cases, hypotension, chest pain, and difficulty breathing can occur. The reaction is highly unpleasant and acts as a pharmacological deterrent to drinking. Severe reactions can be life-threatening — seek emergency medical care if a severe reaction occurs.

Q: Can I drink alcohol a few days after stopping disulfiram?
A: Disulfiram irreversibly inhibits aldehyde dehydrogenase — new enzyme must be synthesised before alcohol can be safely consumed. Enzyme recovery takes approximately 1–2 weeks after stopping disulfiram. Therefore, it is strongly advised to wait at least 14 days after the last disulfiram dose before consuming any alcohol. Resume after discussing with your doctor as part of the overall treatment plan.

Clinical Evidence and Quality Standards

The active ingredient in Dizone 250mg has been evaluated in randomised controlled trials, meta-analyses, and extensive post-marketing surveillance studies supporting its use in the approved indications. Major international clinical guidelines — including those from the British Association of Dermatologists, American Academy of Dermatology, European Dermatology Forum, National Institute for Health and Care Excellence (NICE), and relevant specialty societies — incorporate this drug class in their evidence-based treatment algorithms, reflecting a high level of clinical confidence in its efficacy and safety profile when used appropriately.

Dizone 250mg is manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities. GMP certification ensures consistent product quality, identity, strength, purity, and safety across all manufactured batches. Patients should only obtain prescription medications from licensed pharmacies with a valid prescription to ensure they receive authentic, properly stored, regulatory-compliant products.

Important Medical Disclaimer

This product information page is provided for general educational purposes only, developed in accordance with YMYL (Your Money Your Life) content standards. The information presented draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It is not a substitute for professional medical advice, diagnosis, or treatment from a qualified physician, dermatologist, addiction medicine specialist, or pharmacist. Drug therapy decisions must be individualised based on the complete clinical picture, comorbidities, and concurrent medications of each patient. Self-diagnosis and self-treatment of conditions managed by prescription medications can be dangerous and may lead to delayed diagnosis of serious underlying conditions, inappropriate drug use, or preventable adverse events. Always consult a qualified healthcare professional before starting, changing, or stopping this or any medication.